2010年10－12月期（第4四半期）決算で6億9,000万ポンドの純損失を計上し、前年同期の黒字（16億3,000万ポンド）から赤字に転落。糖尿病治療薬アバンディアの販売が副作用問題で急減したことが大きく響いた。同問題に関する訴訟費用もかさみ、収益を圧迫した。売上高は13％減の71億9,000万ポンド。12月通期の最終損益は16億3,000万ポンドの黒字となったが、黒字幅は前年から70％減少した。売上高は1％減の283億9,000万ポンド。
\
| Cookie | 期間 | 説明 |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |